PRP Kit Buying Guide for Clinicians: What to Evaluate

Platelet-rich plasma has become one of the most widely used autologous biologics in regenerative medicine, with applications spanning orthopedics, sports medicine, dermatology, and aesthetic practice. Yet among the most consequential decisions a clinic makes when adopting PRP is selecting the preparation system. Not all kits produce equivalent platelet concentrations, leukocyte profiles, or growth factor yields. The variability across commercially available systems is well documented in the literature, and understanding the parameters that drive that variability is the starting point for any rigorous procurement process.1

This guide covers the core technical and regulatory considerations practitioners should evaluate before selecting a PRP kit supplier. It is not an endorsement of any specific product or manufacturer.

How PRP Works: Platelet Biology and Growth Factor Release

PRP is an autologous concentrate of platelets in a small plasma volume, prepared from the patient's own whole blood. When activated, platelets degranulate and release a range of bioactive molecules stored in alpha granules, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-beta), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor 1 (IGF-1). These molecules participate in signaling pathways associated with cell migration, proliferation, angiogenesis, and extracellular matrix remodeling.2

The clinical relevance of these signaling properties is the subject of ongoing research across multiple specialties. Results from published trials are mixed and context-dependent, with variation in outcomes attributable in part to differences in preparation protocols, platelet concentration, and activation methods. Understanding how preparation variables influence the final product is therefore central to any evidence-based kit evaluation.3

Key Variables in PRP Kit Performance

PRP kits differ across several dimensions that directly influence the composition of the final concentrate. Evaluating a kit requires understanding how each variable is controlled and what the manufacturer's published data show.

PRP Classification Systems

Several classification frameworks have been proposed in the academic literature to standardize how PRP products are described and compared across studies. The most commonly referenced systems classify PRP by leukocyte content (present or absent), fibrin network characteristics, and whether an exogenous activator is used.

The PAW (Platelets, Activation, White cells) classification and the DEPA (Dose of injected platelets, Efficiency of production, Purity of the concentrate, Activation used) system each attempt to provide a shared vocabulary for comparing preparations across clinical settings. Neither system has achieved universal adoption, and most kit manufacturers do not explicitly align their labeling to a single classification framework.

For practical purchasing decisions, classification frameworks are most useful as a lens for evaluating published efficacy literature. When a published study describes outcomes with "L-PRP at 5x baseline concentration prepared by double-spin protocol," that description maps onto specific kit parameters a clinic can seek to match or deviate from intentionally.3

Activation Methods: Calcium Chloride, Thrombin, and Autologous Clotting

PRP can be delivered in its liquid (anticoagulated) form for injection, or activated prior to use to accelerate platelet degranulation and fibrin network formation. The two main exogenous activators are calcium chloride (CaCl2) and bovine thrombin. Some practitioners also use autologous thrombin derived from the patient's own plasma as an alternative to bovine-derived products.

Bovine thrombin carries a historical regulatory concern around immunogenicity and potential antibody formation, which contributed to its decline in favor of calcium-based activation. Autologous thrombin avoids xenogenic material exposure but requires an additional preparation step. The clinical significance of activation method choice is an ongoing area of investigation, with no consensus on superiority in most application contexts.

A clinically important note: not all PRP applications require pre-activation. Many practitioners deliver anticoagulated PRP directly into tissue, where endogenous collagen and tissue factor initiate platelet activation in situ. Kit specifications should be evaluated in the context of the specific protocol the clinic intends to use.

Closed vs Open Systems: Contamination Risk and Documentation

For most clinic settings, closed systems are the practical default. They are easier to standardize, easier to train staff on, and impose fewer procedural requirements for maintaining sterility. Open systems are more common in academic and research settings where protocol flexibility is a priority.

Regulatory Considerations for In-Office PRP

PRP prepared from a patient's own blood for same-day use may qualify for a regulatory exemption under 21 CFR Part 1271 as a minimally manipulated, homologously used human cell and tissue product (HCT/P). This exemption applies when the processing does not alter the original relevant characteristics of the blood component and the intended use is consistent with the normal function of blood components in autologous applications.

The PRP preparation device (the kit or centrifuge system) is regulated separately from the PRP product itself. Devices used to prepare PRP for in-office use may carry FDA 510(k) clearance for specific indicated uses. Some clearances cover orthopedic applications; others are cleared specifically for wound care or surgical use. Clearance does not extend across all potential application areas, and clinicians are responsible for understanding whether the cleared intended use of a device aligns with their practice.4

Clinicians should also be aware that FDA has issued warning letters to practitioners and manufacturers making unsubstantiated efficacy claims about PRP. Documentation of practitioner decision-making, including literature references, patient selection rationale, and informed consent, is a standard-of-care expectation regardless of regulatory framework.

Supplier Due Diligence Checklist

When evaluating a PRP kit supplier, the following documentation requests are reasonable starting points for due diligence. This list is not exhaustive and does not constitute legal or regulatory advice.

PRP and Exosome-Based Biologics: Complementary Research Directions

As practitioners evaluate PRP systems, many are also reviewing emerging research on MSC-derived exosomes as a complementary or alternative approach in certain protocol contexts. Unlike PRP, exosomes are manufactured biologics from donor mesenchymal stem cells rather than autologous blood components. They require a different supply chain, regulatory framework, and quality documentation standard.

PRP has a substantially longer clinical track record. Exosomes represent an earlier and more exploratory stage of clinical research. Some practitioners report using both in combination protocols, though the research supporting such combinations is limited and largely preclinical. Clinicians considering either approach should review the available literature in their specific application area and consult with qualified legal and regulatory advisors.1

For an overview of how exosomes and PRP differ in hair restoration research specifically, see our related article: Exosomes for Hair Restoration: What the Research Says.

Frequently Asked Questions